fezakinumab   Click here for help

GtoPdb Ligand ID: 9281

Synonyms: ILV-094
Immunopharmacology Ligand
Compound class: Antibody
Comment: Fezakinumab is a fully human monoclonal anti-IL22 antibody being investigated for clinical antiinflammatory utility against acute and chronic conditions.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequences identical to those of the heavy and light variable regions of fezakinumab are claimed in patent US7811567, leading to identification of clone 356A11 as fezakinumab [1].
No information available.
Summary of Clinical Use Click here for help
Fezakinumab (ILV-094) has reached Phase 2 for atopic dermatitis (NCT01941537 ongoing), rheumatoid arthritis (NCT00883896 completed) and Phase 1 for psoriasis (NCT00563524 completed).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
IL-22, an IL-10 superfamily cytokine, plays a key role during inflammatory responses. Blocking or neutralising anti-IL-22 antibodies inhibit IL-22 activity, thereby reducing inflammation. Fezakinumab binds IL-22, effectively preventing formation of the IL-22/IL-22 receptor complex and inhibiting downstream signalling.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00563524 Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis Phase 1 Interventional Wyeth is now a wholly owned subsidiary of Pfizer
NCT00883896 Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis Phase 2 Interventional Pfizer
NCT01941537 Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis Phase 2 Interventional Rockefeller University